Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy

NCT00388700 is registered in ClinicalTrials.gov with Galectin Therapeutics Inc. as lead sponsor.

NCT NCT00388700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00388700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy
Lead sponsor
Galectin Therapeutics Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2006
Completion date
June 30, 2009
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer